RELMADA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Recognition and Exercise
RELMADA THERAPEUTICS, INC. (RLMD) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $11.17 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2023-08-08
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2023-06-30 was $11.17M, a 9.15% decline year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2023-03-31 was $11.35M, a 4.83% decline year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2022-09-30 was $8.34M, a 4.11% increase year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2022-06-30 was $12.30M, a 48.70% increase year-over-year.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2021 was $40.49M, a 94.90% increase from fiscal 2020.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2020 was $20.78M.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2019 was $1.21M, a 134.36% increase from fiscal 2018.
- RELMADA THERAPEUTICS, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2018 was $518.00K, a 26.47% decline from fiscal 2017.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 2 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 12 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 15 month |
|---|---|---|---|---|---|---|
| 2023-06-30 | $11.17M 10-Q · filed 2023-08-08 | $22.52M derived: sum of 2 quarters · filed 2023-08-08 | ||||
| 2023-03-31 | $11.35M 10-Q · filed 2023-08-08 | |||||
| 2022-09-30 | $8.34M 10-Q · filed 2022-11-10 | $20.64M derived: sum of 2 quarters · filed 2023-08-08 | $32.57M derived: sum of 3 quarters · filed 2023-08-08 | |||
| 2022-06-30 | $12.30M 10-Q · filed 2023-08-08 | $24.23M derived: sum of 2 quarters · filed 2023-08-08 | $12.30M 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $11.93M 10-Q · filed 2023-08-08 | |||||
| 2022-03-14 | $110.00K 10-K · filed 2023-03-23 | |||||
| 2021-12-31 | $40.49M 10-K · filed 2022-03-25 | |||||
| 2021-09-30 | $8.01M 10-Q · filed 2022-11-10 | $16.28M derived: sum of 2 quarters · filed 2022-11-10 | $22.13M derived: sum of 3 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $8.27M 10-Q · filed 2022-11-10 | $14.12M derived: sum of 2 quarters · filed 2022-11-10 | ||||
| 2021-03-31 | $5.85M 10-Q · filed 2022-11-10 | |||||
| 2020-12-31 | $20.78M 10-K · filed 2022-03-25 | |||||
| 2020-09-30 | $5.24M 10-Q · filed 2021-11-12 | $12.55M derived: sum of 2 quarters · filed 2021-11-12 | $17.59M derived: sum of 3 quarters · filed 2021-11-12 | $19.20M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $7.30M 10-Q · filed 2021-11-12 | $12.34M derived: sum of 2 quarters · filed 2021-11-12 | $13.95M derived: sum of 3 quarters · filed 2021-11-12 | $14.71M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $5.04M 10-Q · filed 2021-11-12 | $6.65M derived: sum of 2 quarters · filed 2021-11-12 | $7.41M derived: sum of 3 quarters · filed 2021-11-12 | $7.81M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2019-12-31 | $1.61M derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-24 | $2.37M 10-K · filed 2021-03-24 | $2.77M derived: sum of 3 quarters · filed 2021-03-24 | $3.17M derived: sum of 4 quarters · filed 2021-03-24 | ||
| 2019-09-30 | $757.72K 10-Q · filed 2020-11-12 | $1.16M derived: sum of 2 quarters · filed 2020-11-12 | $1.56M derived: sum of 3 quarters · filed 2020-11-12 | $1.82M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $403.46K 10-Q · filed 2020-11-12 | $798.15K derived: sum of 2 quarters · filed 2020-11-12 | $1.06M derived: sum of 3 quarters · filed 2020-11-12 | $1.21M 10-K · filed 2021-03-24 | ||
| 2019-03-31 | $394.69K 10-Q · filed 2020-11-12 | $657.74K derived: sum of 2 quarters · filed 2020-11-12 | $810.54K derived: sum of 3 quarters · filed 2020-11-12 | |||
| 2018-12-31 | $263.04K 10-Q · filed 2019-05-15 | $415.85K 10-KT · filed 2020-03-26 | ||||
| 2018-09-30 | $152.80K 10-Q · filed 2019-11-13 | |||||
| 2018-06-30 | $518.00K 10-KT · filed 2020-03-26 | |||||
| 2018-03-31 | $162.26K 10-Q · filed 2019-05-15 | $296.30K derived: sum of 2 quarters · filed 2019-05-15 | $365.17K derived: sum of 3 quarters · filed 2019-05-15 | |||
| 2017-12-31 | $134.04K 10-Q · filed 2019-05-15 | $202.91K derived: sum of 2 quarters · filed 2019-05-15 | ||||
| 2017-09-30 | $68.87K 10-Q · filed 2019-05-15 | |||||
| 2017-06-30 | $704.45K 10-K · filed 2018-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |